BioCentury
ARTICLE | Clinical News

RayVa alprostadil: Phase IIa data

September 28, 2015 7:00 AM UTC

Top-line data from a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial in about 35 patients with Raynaud’s disease secondary to scleroderma showed that 300, 1,000 and 3,000 ug topical ...